Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Live Virtual MAT 8-Hour Training - Friday, July 17, 2020 (8:00am - 5:00pm Eastern)

    Product not yet rated Contains 6 Component(s), Includes Credits

    8.0 pharmacology contact hours

    image

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.* 


    Course Description: 

    This course is jointly provided by Providers Clinical Support System (PCSS) and American Psychiatric Nurses Association (APNA). The course consists of 8 content topics which are part of the required 24 hours of content for nurses who wish to offer medication assisted treatments for substance use disorders including buprenorphine. This course will be presented in a live virtual format. The final online course post-test, honor statement, overall course evaluation must be completed in order to obtain a certification of completion and an evaluation link for the PCSS web site. 


    Target Audience:
    APRN

    Pricing: Free


    Learning Outcomes:

    Upon completion of the course, learners will be able to:

    1. Identify patients with substance use disorder and discuss medication-assisted treatments.
    2. Discuss the neuroscience of opioids as it relates to treatment of opioid use disorder (OUD) patients.
    3. Describe the basics of office-based medication-assisted treatment including the treatment of special patient populations, such as: adolescents, elderly, pregnancy, pain & psychiatric comorbidities.
    4. Discuss FDA-approved antagonist, partial agonist and agonist medications available to treat OUD.
    5. Explain the process of buprenorphine induction as well as stabilization and maintenance.
    6. Discuss general office protocols including medical record documentation and confidentially.
    7. Apply evidence-based resources when prescribing MAT for patients with OUD. 
    8. Complete 8-hour MAT Course (MDs & DOs) &/or 24-hour MAT Course (APRNs & PAs).
    9. Apply for a MAT Waiver Training Certificate (DEA-X Waiver).
    10. Receive DATA-2000 (DEA-X license) to begin prescribing MAT for OUD per prescriber’s state regulations.

    Nursing Continuing Professional Development:
    8.0 contact hours (of which 8.0 are in pharmacology). In order to receive contact hours for the course, participants must: attend the program in its entirety, earn a passing score of at least 80% on the online post-test, and complete the online honor statement and course evaluation during the allotted 30-day access period. Participants will have 5 opportunities to correctly answer the questions on the post-test. Following completion of the entire live virtual course day, course post-test, honor statement, and course evaluation, a certificate of completion will be generated online, available for immediate printing. Credit will not be earned unless all components of the program are completed. Partial credit will not be awarded. You must be present in the live virtual course environment the entire day.


    Keywords:
     Addictions, MAT Training, Substance Use Disorders

    Register:  

    • The course is free of charge and can be accessed by clicking the Register button above. You will be prompted to login with your APNA account. If you do not have an APNA account, select the button, "create an account" and complete the listed information to create a free non-member profile.
    • After completing the 8 hour and 16-hour waiver training, return to the PCSS website for information on continuing the waiver process, which is outlined in the below infographic. Detailed DEA waiver instructions are provided via email upon completion of all 24 hours of training. Click here for the "Steps to Obtain Your MAT Waiver" process map.  

           Click here for the "Steps to Obtain Your MAT Waiver" process map.


    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    Accreditation of this nursing continuing professional development educational activity does not imply endorsement by APNA or ANCC of any commercial products discussed in the context of this activity. 


    Funding Statement:  
    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Disclosures:

    • The APNA nurse planner and members of the APNA planning committee have no financial relationships or conflict of interest to disclose. Dr. Laura Leahy, faculty, is not receiving commercial/pharmaceutical industry or financial support related to this presentation. Faculty has published through American Psychiatric Publishing, Inc. & receives royalties on her text Manual of Clinical Psychopharmacology for Nurses. Faculty receives honoraria as Nurse Consultant for Alkermes’ Meeting the Need Steering Committee. Faculty receives honoraria for educational presentations as a member of the Speakers’ Bureau for: Otsuka, Alkermes and NEOS Therapeutics. Faculty acknowledges their responsibility to disclose contents of this training program related to the off label or investigative uses of pharmaceutical agents.
    • This educational activity may contain discussion of off-label usage of drugs that are not indicated by the FDA. The APNA and the American Academy of Addiction Psychiatry (AAAP) do not recommend usage of any agent outside the FDA approved/labeled indications. 


    Release Date: July 1, 2020
    The contact hours for this session expire: March 31, 2023

    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.


  • Live Virtual MAT 8-Hour Training - Friday, August 14, 2020 (11:00 am-8:00 pm Eastern)

    Product not yet rated Contains 6 Component(s), Includes Credits

    8.0 pharmacology contact hours

    image


    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.* 

    Course Description: 

    This course is jointly provided by Providers Clinical Support System (PCSS) and American Psychiatric Nurses Association (APNA). The course consists of 8 content topics which are part of the required 24 hours of content for nurses who wish to offer medication assisted treatments for substance use disorders including buprenorphine. This course will be presented in a live virtual format. The final online course post-test, honor statement, overall course evaluation must be completed in order to obtain a certification of completion and an evaluation link for the PCSS web site. 

    Target Audience: APRN 

    Pricing: Free

    Learning Outcomes:
    Upon completion of the course, learners will be able to:

    1. Identify patients with substance use disorder and discuss medication-assisted treatments
    2. Discuss the neuroscience of opioids as it relates to treatment of opioid use disorder (OUD) patients.
    3. Describe the basics of office-based medication-assisted treatment including the treatment of special patient populations, such as: adolescents, elderly, pregnancy, pain & psychiatric comorbidities.
    4. Discuss FDA-approved antagonist, partial agonist and agonist medications available to treat OUD.
    5. Explain the process of buprenorphine induction as well as stabilization and maintenance.
    6. Discuss general office protocols including medical record documentation and confidentially.
    7. Apply evidence-based resources when prescribing MAT for patients with OUD. 
    8. Complete 8-hour MAT Course (MDs & DOs) &/or 24-hour MAT Course (APRNs & Pas).
    9. Apply for a MAT Waiver Training Certificate (DEA-X Waiver)
    10. Receive DATA-2000 (DEA-X license) to begin prescribing MAT for OUD per prescriber’s state regulations.

    Nursing Continuing Professional Development:
    8.0 contact hours (of which 8.0 are in pharmacology). In order to receive contact hours for the course, participants must: attend the program in its entirety, earn a passing score of at least 80% on the online post-test, and complete the online honor statement and course evaluation during the allotted 30-day access period. Participants will have 5 opportunities to correctly answer the questions on the post-test. Following completion of the entire live virtual course day, course post-test, honor statement, and course evaluation, a certificate of completion will be generated online, available for immediate printing. Credit will not be earned unless all components of the program are completed. Partial credit will not be awarded. You must be present in the live virtual course environment the entire day.


    Key Words: Addictions, MAT Training, Substance Use Disorders

    Register:

    • The course is free of charge and can be accessed by clicking the Register button above. You will be prompted to login with your APNA account. If you do not have an APNA account, select the button, "create an account" and complete the listed information to create a free non-member profile.
      After completing the 8 hour and 16-hour waiver training, return to the PCSS website for information on continuing the waiver process, which is outlined in the below infographic. Detailed DEA waiver instructions are provided via email upon completion of all 24 hours of training. Click here for the "Steps to Obtain Your MAT Waiver" process map.
    • Click here for the "Steps to Obtain Your MAT Waiver" process map.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    Accreditation of this nursing continuing professional development educational activity does not imply endorsement by APNA or ANCC of any commercial products discussed in the context of this activity. 


    Funding Statement:  
    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Disclosures:

    • The APNA nurse planner and members of the APNA planning committee have no financial relationships or conflict of interest to disclose. Dr. Laura Leahy, faculty, is not receiving commercial/pharmaceutical industry or financial support related to this presentation. Faculty has published through American Psychiatric Publishing, Inc. & receives royalties on her text Manual of Clinical Psychopharmacology for Nurses. Faculty receives honoraria as Nurse Consultant for Alkermes’ Meeting the Need Steering Committee. Faculty receives honoraria for educational presentations as a member of the Speakers’ Bureau for: Otsuka, Alkermes and NEOS Therapeutics. Faculty acknowledges their responsibility to disclose contents of this training program related to the off label or investigative uses of pharmaceutical agents.
    • This educational activity may contain discussion of off-label usage of drugs that are not indicated by the FDA. The APNA and the American Academy of Addiction Psychiatry (AAAP) do not recommend usage of any agent outside the FDA approved/labeled indications. 

    Release Date: July 1, 2020
    The contact hours for this session expire: March 31, 2023

    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.


  • 203-20: Clinical Practice During COVID-19

    Contains 5 Component(s), Includes Credits

    Presenters: Georgia L. Stevens, PhD, APRN, PMHCNS-BC , Joseph M. Holshoe BS, BSN, MA, MSN, PMHNP-BC, Barbara Jones Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN, Brittany Evans Yates, DNP, APRN, PMHNP-BC 0.5 contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    203-20:  Clinical Practice During COVID-19

    Gain an understanding of how the COVID-19 pandemic has impacted clinical practice, how to better serve patients during this time, and how to anticipate and prepare for its longer term impacts.


    Presenters:
      Georgia L. Stevens, PhD, APRN, PMHCNS-BC , Joseph M. Holshoe BS, BSN, MA, MSN, PMHNP-BC, Barbara Jones Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN, Brittany Evans Yates, DNP, APRN, PMHNP-BC

    Disclosures:  The presenters and planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will not be discussed during this presentation.


    Session Length:
      29 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    • Discuss the impact of COVID-19 on providers in clinical practice and the people they serve. 

    Keywords:  Self-Care, Current Trends, Practice


    Nursing Continuing Professional Development:
    0.5 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 404-20: Best Practices for Serving and Supporting Gender Diverse Patients

    Product not yet rated Contains 5 Component(s), Includes Credits

    Presenter: Rhonda Schwindt, DNP, RN, PMHNP/CNS-BC 1.0 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    404-20: Best Practices for Serving and Supporting Gender Diverse Patients

    Examine best practices for psychopharmacological interventions for transgender and gender nonconforming individuals. Apply strategies to build partnerships with this underserved population to reduce barriers to help-seeking.


    Presenter:
     Rhonda Schwindt, DNP, RN, PMHNP/CNS-BC

    Disclosures:  The presenters and planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will not be discussed during this presentation.


    Session Length:
      1 hour

    Target Audience:  RN, APRN


    Learning Outcome:
    Upon completion of this presentation, the participant will be able to:

    • Examine the role of the advance practice nurse in the care and support of gender-diverse patients, and their unique pharmacological considerations.

    Keywords:  Gender, Diversity, Transgender, Gender Dysphoria, SOGI


    Nursing Continuing Professional Development:
    1.0 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 201-20: The Medication Interest Model (MIM): A Transformative Shared Decision Making Model

    Product not yet rated Contains 5 Component(s), Includes Credits

    Presenter: Shawn Christopher Shea, M.D. 2.25 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    201-20: The Medication Interest Model (MIM): A Transformative Shared Decision Making Model 

    A clinical interviewing approach for simultaneously forging the therapeutic alliance while enhancing medication understanding, interest, and follow-through. Over 100 easily learned and easily taught techniques for talking with patients about medications from initially describing one’s approach to prescribing medications to uncovering a patient’s true concerns about side effects to enhancing medication adherence through the use of a new motivational theory (the Choice Triad).


    Presenter: Shawn Christopher Shea, M.D. 

    Disclosures: Author Royalties from Elsevier and Wolters-Kluwer. The presenter and planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will not be discussed during this presentation.


    Session Length:
      2 hours 14 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    • Describe a variety of interviewing techniques that allow clinicians to more effectively build a therapeutic alliance while  enhancing medication interest and effective use. 

    Keywords:  Communication, Relationship, Prescribing 


    Nursing Continuing Professional Development:
    2.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 301-20: Improving Patient Outcomes in Schizophrenia

    Contains 5 Component(s), Includes Credits

    Presenter: Christoph U. Correll, M.D. 1.5 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    301-20:  Improving Patient Outcomes in Schizophrenia

    Review the evidence on best approaches for caring for individuals with schizophrenia, including acute, mid-, and long-term therapy options. Understand the risks, benefits, and effectiveness of psychopharmacologic interventions for schizophrenia.


    Presenter:
      Christoph U. Correll, M.D.

    Disclosures:  The presenter has disclosed a relationship with Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. The planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will be discussed during this presentation.


    Session Length: 1 hour 31 minutes 

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    • Describe and apply the ranking of different pharmacologic treatments for schizophrenia regarding acute and long-term efficacy, tolerability, and quality of life.

    Keywords:  Schizophrenia


    Nursing Continuing Professional Development:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 101-20: Turning Down the Heat: Psychopharmacologic Management of Irritability through Aggression

    Contains 5 Component(s), Includes Credits

    Presenter: Julie A Carbray PhD, FPMHNP-BC, PMHCNS-BC, APN 1.75 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*


    101-20: Turning Down the Heat: Psychopharmacologic Management of Irritability through Aggression

    This course discusses the psychopharmacology and utility of agents used for the management of irritability through aggression. Strategies from this course can be applied across diagnoses and for both acute and outpatient settings. You will explore neurotransmitters, particularly glutamate and GABA, from a psychopharmacological perspective. You’ll also leave this course with a better understanding of how this neurobiology relates to the lived experience of persons with mental health disorders.

    Presenter:  Julie A Carbray PhD, FPMHNP-BC, PMHCNS-BC, APN 

    Disclosures:  The presenter served on an advisory board for Alkermes and Supernus. The planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will be discussed during this presentation.


    Session Length:
      1 hour 40 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    • Describe the neurobiology behind irritability, aggression and rage, and determine when a psychotropic medication may be indicated.

    Keywords: Irritability, Aggression, Rage, Psychotropic Medications


    Nursing Continuing Professional Development:
    1.75 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 302-20: Perinatal Mood and Anxiety Disorders: Walking the Tightrope of Care

    Product not yet rated Contains 5 Component(s), Includes Credits

    Presenter: Kathryn S. Johnson, MSN, PMHCNS-BC, PMHNP-BC 1.5 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    302-20: Perinatal Mood and Anxiety Disorders: Walking the Tightrope of Care

    This presentation will discuss the assessment and management of mood and anxiety symptoms throughout pregnancy and for the first year after birth.


    Presenter:
      Kathryn S. Johnson, MSN, PMHCNS-BC, PMHNP-BC

    Disclosures:  The presenter and planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will not be discussed during this presentation.


    Session Length:
      1 hour 28 minutes

    Target Audience:  RN, APRN


    Learning Outcome:
    Upon completion of this presentation, the participant will be able to:

    • Explore current APA/ACOG Guidelines for the treatment of perinatal mood and anxiety disorders.

    Keywords:  ACOG, PPD, Perinatal, Teratogenic 


    Nursing Continuing Professional Development:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 303-20: Drug Interactions: Psychotropic Medications, Supplements, and Herbal Products

    Product not yet rated Contains 5 Component(s), Includes Credits

    Presenter: Mary A. Gutierrez, PharmD, BCPP 1.5 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    303-20: Drug Interactions:  Psychotropic Medications, Supplements, and Herbal Products

    Identify strategies to minimize or avoid psychotropic drug interactions with prescription medications, supplements, and herbal products. Determine potential impact of adding these products to an existing drug regimen.


    Presenter:
      Mary A. Gutierrez, PharmD, BCPP

    Disclosures:  The presenter and planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will be discussed during this presentation.


    Session Length:
      1 hour 38 minutes

    Target Audience:  RN, APRN


    Learning Outcome:
    Upon completion of this presentation, the participant will be able to:

    • Identify strategies to avoid or minimize psychotropic drug interactions with prescription medications, supplements and herbal products.

    Keywords:  Psychotropic Drug, Interactions, Supplements, Herbal Products

    Nursing Continuing Professional Development:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

  • 304-20: Recognition, Assessment and Treatment of Movement Disorders

    Product not yet rated Contains 5 Component(s), Includes Credits

    Presenter: Rebecca S. Roma, MD, MBA 1.25 pharmacology contact hours

    For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

    304-20: Recognition, Assessment and Treatment of Movement Disorders

    Analyze different presentations of drug induced movement disorders and look at treatment options including dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia.


    Presenter:  Rebecca S. Roma, MD, MBA

    Disclosures:  The presenter has indicated a significant financial interest or other affiliation with Alkermes, Janssen Pharmaceuticals Inc., Neurocrine, Teva and Otsuka America Pharmaceutical. The activity planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will not be discussed during this presentation.


    Session Length:
      1 hour 12 minutes

    Target Audience:  RN, APRN


    Learning Outcome:
    Upon completion of this presentation, the participant will be able to:

    • Identify movement disorders caused by common psychiatric medications.

    Keywords:  AIMS Scale, EPS, Akathesia Dystonia


    Nursing Continuing Professional Development:
    1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


    The contact hours for this session expire:  June 30, 2022


    *Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.